Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 subcutaneous daratumumab in Japanese patients with relapsed or refractory multiple myeloma
jRCT2080223609Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Aug 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of daratumumab in multiple myeloma (MM), sponsored by Janssen Pharmaceutical. Started Aug 2017; status: completed.
02
Drugs
daratumumab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on jRCT2080223609.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223609.